The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Aortic valve disease and treatment: The need for naturally engineered solutions
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The incidence of congenital heart disease.
Hoffman, J. I. E., & Kaplan, S. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01886-7 · Cited by 6,099
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140
Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., & Breslow, J. L. (1992) · Cell · doi:10.1016/0092-8674(92)90362-g · Cited by 2,263
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 1×
“Because of the supposed similarities in disease progression and common risk factors with atherosclerosis, the primary candidates for pharmacological treatment of valve disease have been lipid lowering agents and angiotensin-converting enzyme (ACE) inhibitors [97,140].”
BackgroundAngiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Biodegradable synthetic polymers for tissue engineering
CSIRO Molecular Science, B. 1., & Gunatillake, P. (2003) · European Cells and Materials · doi:10.22203/ecm.v005a01 · Cited by 1,765 · cited 1×
“An additional concern is that the end products from the degrading acidic polymers change local pH, causing undesired cell death and differentiation [442].”
BackgroundIntensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Mutations in NOTCH1 cause aortic valve disease
Garg, V., Muth, A. N., Ransom, J. F., Schluterman, M. K., Barnes, R., King, I. N., Grossfeld, P. D., & Srivastava, D. (2005) · Nature · doi:10.1038/nature03940 · Cited by 1,509
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
Roberts, W. C., & Ko, J. M. (2005) · Circulation · doi:10.1161/01.cir.0000155623.48408.c5 · Cited by 1,000
Carabello, B. A., & Paulus, W. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60211-7 · Cited by 818
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479 · cited 2×
“These include weight loss drugs (fenfluramine and dexfenfluramine); drugs used to treat migraine headaches (ergot alkaloids, ergotamine, and methysergide); ergot-derived dopaminergic compounds used for Parkinson's disease, restless legs syndrome, and hyperprolactinemic disorders (pergolide and cabergoline); and the am…”
BackgroundRieder, E., Kasimir, M.-T., Silberhumer, G., Seebacher, G., Wolner, E., Simon, P., & Weigel, G. (2004) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2003.06.017 · Cited by 430
Presence of Oxidized Low Density Lipoprotein in Nonrheumatic Stenotic Aortic Valves
Olsson, M., Thyberg, J., & Nilsson, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1218 · Cited by 417
Tenascin-X deficiency is associated with Ehlers-Danlos syndrome
Burch, G. H., Gong, Y., Liu, W., Dettman, R. W., Curry, C. J., Smith, L., Miller, W. L., & Bristow, J. (1997) · Nature Genetics · doi:10.1038/ng0997-104 · Cited by 366
Liberman, M., Bassi, E., Martinatti, M. K., Lario, F. C., Wosniak, J., Pomerantzeff, P. M. A., & Laurindo, F. R. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.156745 · Cited by 225
Mohty, D., Pibarot, P., Després, J.-P., Côté, C., Arsenault, B., Cartier, A., Cosnay, P., Couture, C., & Mathieu, P. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.154989 · Cited by 181
Induction of Autoimmune Valvular Heart Disease by Recombinant Streptococcal M Protein
Quinn, A., Kosanke, S., Fischetti, V. A., Factor, S. M., & Cunningham, M. W. (2001) · Infection and Immunity · doi:10.1128/iai.69.6.4072-4078.2001 · Cited by 151
Wnt signaling in heart valve development and osteogenic gene induction
Alfieri, C. M., Cheek, J., Chakraborty, S., & Yutzey, K. E. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2009.11.030 · Cited by 138
Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves
Helske, S., Syväranta, S., Kupari, M., Lappalainen, J., Laine, M., Lommi, J., Turto, H., Mäyränpää, M., Werkkala, K., Kovanen, P. T., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi706 · Cited by 129
Malfait, F., Symoens, S., Coucke, P., Nunes, L., De Almeida, S., & De Paepe, A. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.038224 · Cited by 124
Cited by
3D Bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels
Duan, B., Hockaday, L. A., Kang, K. H., & Butcher, J. T. (2013) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.34420 · Cited by 1,002
Self-citationHockaday, L. A., Kang, K. H., Colangelo, N. W., Cheung, P. Y. C., Duan, B., Malone, E., Wu, J., Girardi, L. N., Bonassar, L. J., Lipson, H., et al. (2012) · Biofabrication · doi:10.1088/1758-5082/4/3/035005 · Cited by 683
Self-citationEngineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
Poly(lactic acid) nanofibrous scaffolds for tissue engineering
Santoro, M., Shah, S. R., Walker, J. L., & Mikos, A. G. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.019 · Cited by 485
Duan, B., Kapetanovic, E., Hockaday, L. A., & Butcher, J. T. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.12.005 · Cited by 436
Self-citation
Metadata
- Authors
- Butcher, J. T., Mahler, G. J., & Hockaday, L. A.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 63
- Issue
- 4-5
- Pages
- 242-268
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2115053071
- Cited by
- 210
- References
- 27
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.